- Conditions
- Hemophilia A or B With Inhibitors, Hemophilia A, Hemophilia B
- Interventions
- Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 4 Years to 65 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 113
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hemophilia B
- Interventions
- IB1001, nonacog alfa
- Biological
- Lead sponsor
- Medexus Pharma, Inc.
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 10
- States / cities
- Duarte, California • Los Angeles, California • Atlanta, Georgia + 7 more
- Conditions
- Hemophilia B
- Interventions
- verbrinacogene setparvovec
- Genetic
- Lead sponsor
- Spur Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan
- Conditions
- Congenital Bleeding Disorder, Haemophilia B
- Interventions
- N9-GP, ALPROLIX®
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 70 Years · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Chicago, Illinois • Peoria, Illinois + 4 more
- Conditions
- Heparin-induced Thrombocytopenia
- Interventions
- Danaparoid Sodium, Argatroban
- Drug
- Lead sponsor
- Aspen Global Incorporated
- Industry
- Eligibility
- 2 Weeks to 100 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- Gainesville, Florida • Minneapolis, Minnesota • Durham, North Carolina + 2 more
- Conditions
- Acute Bleeding on Long-Term Anticoagulation Therapy, Hemorrhage, Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time), Urgent Reversal of Vitamin K Antagonist (VKA) Anticoagulation
- Interventions
- 4-factor prothrombin complex concentrate (4FPCC)
- Drug
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 18 Years to 125 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- Ataluren
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 7
- States / cities
- Peoria, Illinois • Indianapolis, Indiana • Worcester, Massachusetts + 4 more
- Conditions
- Hemophilia B
- Interventions
- rFIXFc
- Biological
- Lead sponsor
- Bioverativ, a Sanofi company
- Industry
- Eligibility
- Up to 17 Years · Male only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 11
- States / cities
- Sacramento, California • Washington D.C., District of Columbia • Atlanta, Georgia + 8 more
- Conditions
- Hemophilia A With Inhibitors
- Interventions
- activated prothrombin complex concentrate (FEIBA)
- Drug
- Lead sponsor
- Tulane University School of Medicine
- Other
- Eligibility
- 24 Months and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Bleeding Cardiac Surgery Patients
- Interventions
- Octaplex, Frozen Plasma Product, Human
- Drug
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Oklahoma City, Oklahoma
- Conditions
- Hemophilia B, Hemophilia A
- Interventions
- Standard of Care FIX Replacement therapy, Standard of Care FVIII Replacement therapy
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 64 Years · Male only
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 13
- States / cities
- Palo Alto, California • San Francisco, California • Stanford, California + 7 more
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- Non-treatment, seroprevalence
- Other
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Aurora, Colorado • East Lansing, Michigan + 4 more
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- ADVATE (Antihemophilic Factor [Recombinant]), RIXUBIS (Coagulation Factor IX [Recombinant])
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 13 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 17
- States / cities
- Los Angeles, California • San Diego, California • Aurora, Colorado + 14 more
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- marstacimab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 1 Year to 17 Years · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Cardiac Disease, Cardiac Surgery, Cardiopulmonary Bypass, Platelet Transfusion, Arrythmia, Cardiac, Mortality
- Interventions
- Platelet Transfusion, FFP and Cryoprecipitate, PRBC and cell saver Transfusion, Factor Concentrate (Bebulin)
- Biological
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 1 Day to 3 Months
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- Testing of hepatic AAV Vector integration
- Diagnostic Test
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2040
- U.S. locations
- 15
- States / cities
- Rancho Cordova, California • Sacramento, California • San Francisco, California + 6 more
- Conditions
- Vitamin K-Dependent Coagulation Defect, Significant Bleeding Risk
- Interventions
- Balfaxar, Kcentra
- Drug
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,574 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hemophilia A With Inhibitors, Hemophilia B With Inhibitors
- Interventions
- Coagulation FVIIa (Recombinant)
- Biological
- Lead sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
- Industry
- Eligibility
- Up to 11 Years · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Oklahoma City, Oklahoma • Dallas, Texas
- Conditions
- Heart Disease End Stage, Heart Failure，Congestive
- Interventions
- Kcentra, Frozen Plasma Product, Human
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Pittsburgh, Pennsylvania
- Conditions
- Hemophilia
- Interventions
- Fitusiran
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 281 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 7 more
- Conditions
- Hemophilia, Menstrual Flow Excessive
- Interventions
- Recombinant FVIII Fc fusion product Eloctate, Recombinant FIX Fc fusion product Alprolix, Patient-operated diagnostic device for anemia AnemoCheck.
- Drug · Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 14 Years to 55 Years · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Hemophilia
- Interventions
- Coagulation Factor VIIa (Recombinant)
- Biological
- Lead sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
- Industry
- Eligibility
- 12 Years to 65 Years · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Atlanta, Georgia • New Orleans, Louisiana + 2 more
- Conditions
- Transgenderism
- Interventions
- Transdermal patch, Pro-thrombotic markers, Metabolic markers, Hormone Profile, Daily Sublingual Tablet, BID Sublingual Tablet, Spironolactone
- Drug · Diagnostic Test
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 30 Years · Male only
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Cardiopulmonary Bypass
- Interventions
- Recombinant activated factor VII, Prothrombin Complex Concentrate
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- Up to 30 Days
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia